Apposite Capital-backed 1MED, an international contract research organisation offering pre-clinical, regulatory and clinical services for medical device and pharmaceutical companies, has appointed Janet Kube as chief executive.

Kube has more than 25 years’ industry experience, most recently as part of the European senior leadership team at Premier Research. Her experience covers both the medtech and the pharmaceutical realm of research.

Andrea Biffi, chair of 1MED said: “Janet is a dynamic leader with the experience and vision to lead 1MED into its next chapter of growth and innovation. We are confident that under her guidance, we will continue to deliver exceptional value to our customers, employees and shareholders.”

Kube commented: “Over the past 25 years I had the privilege of working with incredibly talented teams across different therapeutic areas and geographies, and I am very impressed by the foundation built to date at 1MED. As we look to the future, I believe we can reach new heights by focusing and building on existing strengths in this rapidly evolving industry landscape.”

Anne-Laure Meynier, partner at Apposite Capital added: “Janet’s vast experience and leadership skills will be pivotal as we continue our ambitious expansion plan and build upon the impressive progress made to date.”

1MED was established in 2014 and is headquartered in Agno, Switzerland.